Bertelmann, Thomas

[["dc.bibliographiccitation.firstpage","e933"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","e941"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Berk, Hüsnü"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Rose, Uwe"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2020-12-10T18:26:52Z"],["dc.date.available","2020-12-10T18:26:52Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/aos.13770"],["dc.identifier.issn","1755-375X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76197"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2167"],["dc.bibliographiccitation.journal","Clinical Ophthalmology"],["dc.bibliographiccitation.lastpage","2179"],["dc.bibliographiccitation.volume","Volume 13"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Ziemssen, Focke"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Voegeler, Jessica"],["dc.contributor.author","Koch, Mirja"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Liakopoulos, Sandra"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Spital, Georg"],["dc.date.accessioned","2020-12-10T18:43:01Z"],["dc.date.available","2020-12-10T18:43:01Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.2147/OPTH.S209253"],["dc.identifier.eissn","1177-5483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78165"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.relation.eissn","1177-5483"],["dc.title","Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","923"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Graefe s Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","934"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Bretag, Mirko"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Goldammer, Lena"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2018-11-07T10:24:17Z"],["dc.date.available","2018-11-07T10:24:17Z"],["dc.date.issued","2017"],["dc.description.abstract","Purpose To evaluate prospectively the efficacy and safety of a fixed bimonthly ranibizumab treatment regimen (RABIMO) in eyes with neovascular age-related macular degeneration (nAMD) and to compare these results with a pro re nata (PRN) treatment scheme. Methods This was a 12-month, phase IV, single center, randomised, non-inferiority study. Following three initial monthly injections, patients were randomised to receive either ranibizumab bimonthly (RABIMO group) or ranibizumab PRN (PRN group) (n = 20 each). Main outcome measures were best-corrected visual acuity (BCVA), central retinal thickness (CRT), number of injections, and adverse events (AEs). Results BCVA [median (interquartile range, IQR)] increased significantly in both groups after 12 months [RABIMO group +8.5 (14); PRN group +6.5 (16) ETDRS letters] when compared to baseline (p < 0.0001; p = 0.0085). At month 12, the RABIMO treatment regimen was non-inferior to the PRN scheme (Delta BCVA = 3.5 ETDRS letters; p < 0.0001). CRT was significantly reduced in both groups after the 12-month study period (p < 0.0001 each), with no significant difference between groups (p = 0.6772). Number of overall injections [median (IQR)] was 8 (0) in the RABIMO versus 4 (5) in the PRN group (p = 0.0037). Three patients in the RABIMO group received one additional unscheduled injection. We observed no significant differences between groups in the number of patients with reported SAEs/AEs (RABIMO group n = 6/15; PRN group n = 7/13) (p = 0.7357/p = 0.4902). Conclusions We found no evidence of significant functional or anatomical differences between the RABIMO and PRN treatment regimens. However, the RABIMO group's number of injections was twice as high as the PRN group's (protocol-driven). In light of potential side effects, the fixed bimonthly treatment regimen might not be advisable for routine clinical care, but it might be a worthwhile treatment option if monthly monitoring is not possible. Eudra-CT number: 2009-017324-11."],["dc.description.sponsorship","Novartis Pharma GmbH, Germany"],["dc.identifier.doi","10.1007/s00417-017-3589-x"],["dc.identifier.isi","000401436500008"],["dc.identifier.pmid","28102456"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42627"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1435-702X"],["dc.relation.issn","0721-832X"],["dc.title","Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","913"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Graefe's Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","920"],["dc.bibliographiccitation.volume","257"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Atili, Abed"],["dc.contributor.author","Striebe, Nina Antonia"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Bertelmann, Thomas"],["dc.date.accessioned","2020-12-10T14:10:34Z"],["dc.date.available","2020-12-10T14:10:34Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s00417-018-04223-9"],["dc.identifier.eissn","1435-702X"],["dc.identifier.issn","0721-832X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70802"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0181766"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","PloS one"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Ammermann, Antje"],["dc.contributor.author","Ganser, Janina"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Duvinage, Andre"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Wachter, Rolf"],["dc.date.accessioned","2019-07-09T11:43:38Z"],["dc.date.available","2019-07-09T11:43:38Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: Patients with retinal vascular occlusion disease have an increased risk for ischemic stroke and share some risk factors with cerebrovascular disease. The purpose of this study was to analyze the prevalence of atrial fibrillation (AF) in subjects with retinal vascular occlusive disease and anterior ischemic optic neuropathy and to compare these data to an ischemic stroke group. METHODS: Prospective, observational single-center trial. Subjects with retinal artery occlusion (RAO), retinal vein occlusion (RVO) and anterior ischemic optic neuropathy (AION) were included. Patients with ischemic stroke (IS) from a previous observational trial were used as control. Investigation included 7-day Holter ECG, echocardiography, duplex ultrasonography of the carotid arteries, and 24-hour blood pressure monitoring. Further vascular risk factors were documented. RESULTS: During the 1-year study period, 101 patients were recruited. The control group with ischemic stroke consisted of 272 subjects. At inclusion, the prevalence of AF was 12% (RAO), 10.2% (RVO), 11.1% (NAION) and 15.8% (IS). The final prevalence after Holter ECG rose to 16% (RAO), 18.4% (RVO), 14.8% (NAION) and 26.5% (IS). No significant difference was measured between groups. CONCLUSIONS: We detected a similar prevalence of AF in all groups. RVO patients tended to exhibit a higher AF detection rate and lower number needed to screen than RAO and NAION. The detection of AF rose considerably via Holter ECG. As a consequence, we recommend prolonged ECG monitoring in patients with acute ophthalmic vascular diseases."],["dc.identifier.doi","10.1371/journal.pone.0181766"],["dc.identifier.pmid","28771491"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14599"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58930"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","961"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Graefe's Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","969"],["dc.bibliographiccitation.volume","258"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Striebe, Nina Antonia"],["dc.contributor.author","Khattab, Mohammed Haitham"],["dc.contributor.author","Affeldt, Johannes"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2020-12-10T14:10:35Z"],["dc.date.available","2020-12-10T14:10:35Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00417-019-04554-1"],["dc.identifier.eissn","1435-702X"],["dc.identifier.issn","0721-832X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70806"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Risk of perioperative bleeding complications in rhegmatogenous retinal detachment surgery: a retrospective single-center study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]